{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:24:50Z","timestamp":1769603090404,"version":"3.49.0"},"reference-count":33,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["CEECIND\/00201\/2017"],"award-info":[{"award-number":["CEECIND\/00201\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/111321\/2015"],"award-info":[{"award-number":["SFRH\/BD\/111321\/2015"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MED-ONC\/31438\/2017"],"award-info":[{"award-number":["PTDC\/MED-ONC\/31438\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-016390"],"award-info":[{"award-number":["POCI-01-0145-FEDER-016390"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Norte 2020 \u2014Programa Operacional Regional do Norte","award":["NORTE-01-0145-FEDER-000029"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000029"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Telomerase reverse transcriptase gene promoter (TERTp) mutations are recognized as one of the most frequent genetic events in bladder cancer (BC). No studies have focused on the relevance of TERTp mutations in the specific group of tumors treated with Bacillus Calmette\u2013Gu\u00e9rin (BCG) intravesical therapy. Methods \u2014 125 non muscle invasive BC treated with BCG therapy (BCG-NMIBC) were screened for TERTp mutations, TERT rs2853669 single nucleotide polymorphism, and Fibroblast Growth Factor Receptor 3 (FGFR3) hotspot mutations. Results \u2014 TERTp mutations were found in 56.0% of BCG-NMIBC and were not associated with tumor stage or grade. FGFR3 mutations were found in 44.9% of the cases and were not associated with tumor stage or grade nor with TERTp mutations. The TERT rs2853669 single nucleotide polymorphism was associated with tumors of higher grade. The specific c.1-146G&gt;A TERTp mutation was an independent predictor of nonrecurrence after BCG therapy (hazard ratio\u20140.382; 95% confidence interval\u20140.150\u20130.971, p = 0.048). Conclusions \u2014 TERTp mutations are frequent in BCG-NMIBC and -146G&gt;A appears to be an independent predictive marker of response to BCG treatment with an impact in recurrence-free survival.<\/jats:p>","DOI":"10.3390\/ijms21030947","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T11:55:56Z","timestamp":1580471756000},"page":"947","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients"],"prefix":"10.3390","volume":"21","author":[{"given":"Rui","family":"Batista","sequence":"first","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), 4200-135 Porto, Portugal"},{"name":"Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal"},{"name":"Faculdade de Medicina da Universidade do Porto (FMUP), 4200-319 Porto, Portugal"}]},{"given":"Lu\u00eds","family":"Lima","sequence":"additional","affiliation":[{"name":"Grupo de Patologia e Terap\u00eautica Experimental, Instituto Portugu\u00eas de Oncologia do Porto FG, EPE (IPO-Porto), 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0871-1427","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Vinagre","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), 4200-135 Porto, Portugal"},{"name":"Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal"},{"name":"Faculdade de Medicina da Universidade do Porto (FMUP), 4200-319 Porto, Portugal"}]},{"given":"Vasco","family":"Pinto","sequence":"additional","affiliation":[{"name":"Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal"},{"name":"Faculdade de Medicina da Universidade do Porto (FMUP), 4200-319 Porto, Portugal"}]},{"given":"Joana","family":"Lyra","sequence":"additional","affiliation":[{"name":"Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal"},{"name":"Faculdade de Medicina da Universidade do Porto (FMUP), 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8631-8356","authenticated-orcid":false,"given":"Valdemar","family":"M\u00e1ximo","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), 4200-135 Porto, Portugal"},{"name":"Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal"},{"name":"Faculdade de Medicina da Universidade do Porto (FMUP), 4200-319 Porto, Portugal"}]},{"given":"L\u00facio","family":"Santos","sequence":"additional","affiliation":[{"name":"Grupo de Patologia e Terap\u00eautica Experimental, Instituto Portugu\u00eas de Oncologia do Porto FG, EPE (IPO-Porto), 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9607-6998","authenticated-orcid":false,"given":"Paula","family":"Soares","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), 4200-135 Porto, Portugal"},{"name":"Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal"},{"name":"Faculdade de Medicina da Universidade do Porto (FMUP), 4200-319 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"J. Int. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00345-009-0383-3","article-title":"The present and future burden of urinary bladder cancer in the world","volume":"27","author":"Ploeg","year":"2009","journal-title":"World J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy","volume":"56","author":"Burger","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrurol.2011.193","article-title":"Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?","volume":"9","author":"Netto","year":"2011","journal-title":"Nat. Rev. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatr. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1073\/pnas.1303607110","article-title":"TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal","volume":"110","author":"Killela","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1530\/ERC-13-0210","article-title":"Highly prevalent TERT promoter mutations in aggressive thyroid cancers","volume":"20","author":"Liu","year":"2013","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/ncomms3185","article-title":"Frequency of TERT promoter mutations in human cancers","volume":"4","author":"Vinagre","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/ncomms3218","article-title":"High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions","volume":"4","author":"Nault","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/modpathol.2013.168","article-title":"TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas","volume":"27","author":"Griewank","year":"2014","journal-title":"Mod. Pathol.: Off. J. US Can. Acad. Pathol. Inc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2013.08.052","article-title":"Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome","volume":"65","author":"Allory","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.eururo.2013.08.057","article-title":"Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine","volume":"65","author":"Hurst","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/modpathol.2013.167","article-title":"Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma","volume":"27","author":"Scott","year":"2014","journal-title":"Mod. Pathol.: Off. J. US Can. Acad. Pathol. Inc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.4161\/cc.24662","article-title":"Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma","volume":"12","author":"Liu","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1158\/0008-5472.CAN-13-2498","article-title":"TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine","volume":"73","author":"Kinde","year":"2013","journal-title":"Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17426","DOI":"10.1073\/pnas.1310522110","article-title":"TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism","volume":"110","author":"Rachakonda","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2013.10.038","article-title":"Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study","volume":"65","author":"Wu","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.18632\/oncotarget.6331","article-title":"The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer","volume":"7","author":"Ko","year":"2016","journal-title":"Oncotarget"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/ijc.30057","article-title":"The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism","volume":"139","author":"Batista","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"181987","DOI":"10.1155\/2012\/181987","article-title":"Bladder Cancer Immunotherapy: BCG and Beyond","volume":"2012","author":"Askeland","year":"2012","journal-title":"Adv. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00345-011-0681-4","article-title":"Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy","volume":"29","author":"Yates","year":"2011","journal-title":"World J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0002-9440(10)64665-2","article-title":"Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors","volume":"158","author":"Billerey","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molcel.2006.04.006","article-title":"p53 Stabilization and Transactivation by a von Hippel-Lindau Protein","volume":"22","author":"Roe","year":"2006","journal-title":"Mol. Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/cas.12075","article-title":"Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine","volume":"104","author":"Kawai","year":"2013","journal-title":"Cancer Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2007.08.122","article-title":"History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story","volume":"179","author":"Herr","year":"2008","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/316951","article-title":"Mutational Analysis in a Cohort of 224 Tuberous Sclerosis Patients Indicates Increased Severity of TSC2, Compared with TSC1, Disease in Multiple Organs","volume":"68","author":"Dabora","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s101470200024","article-title":"BCG effects on telomerase activity in bladder cancer cell lines","volume":"7","author":"Saitoh","year":"2002","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_32","unstructured":"Davis, C.J., Woodward, P.J., Dehner, L.P., Eble, J.N., Sauter, G., and Epstein, J.I. (2004). WHO Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. IARC Press, 267\u2013276."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.urolonc.2013.10.012","article-title":"The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure","volume":"32","author":"Lima","year":"2014","journal-title":"Urol. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/3\/947\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:53:26Z","timestamp":1760172806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/3\/947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,31]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["ijms21030947"],"URL":"https:\/\/doi.org\/10.3390\/ijms21030947","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,31]]}}}